BRPI0813625A2 - Imidazo-[1,2b]-piridozinas 2,3,7-substituídos para tratamento de doenças mediadas por alzk4 ou alk5 - Google Patents
Imidazo-[1,2b]-piridozinas 2,3,7-substituídos para tratamento de doenças mediadas por alzk4 ou alk5Info
- Publication number
- BRPI0813625A2 BRPI0813625A2 BRPI0813625-4A2A BRPI0813625A BRPI0813625A2 BR PI0813625 A2 BRPI0813625 A2 BR PI0813625A2 BR PI0813625 A BRPI0813625 A BR PI0813625A BR PI0813625 A2 BRPI0813625 A2 BR PI0813625A2
- Authority
- BR
- Brazil
- Prior art keywords
- diseases mediated
- pyridozins
- alzk4
- alk5
- imidazo
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102100034134 Activin receptor type-1B Human genes 0.000 abstract 1
- 101710173011 Activin receptor type-1B Proteins 0.000 abstract 1
- 101000712674 Homo sapiens TGF-beta receptor type-1 Proteins 0.000 abstract 1
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
- 239000012453 solvate Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07113214 | 2007-07-26 | ||
| PCT/EP2008/059705 WO2009013335A1 (en) | 2007-07-26 | 2008-07-24 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0813625A2 true BRPI0813625A2 (pt) | 2014-12-23 |
Family
ID=38694831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0813625-4A2A BRPI0813625A2 (pt) | 2007-07-26 | 2008-07-24 | Imidazo-[1,2b]-piridozinas 2,3,7-substituídos para tratamento de doenças mediadas por alzk4 ou alk5 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8143253B2 (pt) |
| EP (1) | EP2183027B1 (pt) |
| JP (1) | JP5090528B2 (pt) |
| KR (1) | KR101150581B1 (pt) |
| CN (1) | CN101765442B (pt) |
| AT (1) | ATE522249T1 (pt) |
| AU (1) | AU2008280135B2 (pt) |
| BR (1) | BRPI0813625A2 (pt) |
| CA (1) | CA2694261A1 (pt) |
| CL (1) | CL2008002184A1 (pt) |
| CO (1) | CO6290714A2 (pt) |
| CR (1) | CR11207A (pt) |
| EA (1) | EA201000123A1 (pt) |
| EC (1) | ECSP109898A (pt) |
| ES (1) | ES2375425T3 (pt) |
| MA (1) | MA31571B1 (pt) |
| PE (1) | PE20090506A1 (pt) |
| SV (1) | SV2010003463A (pt) |
| TN (1) | TN2010000040A1 (pt) |
| TW (1) | TW200911814A (pt) |
| WO (1) | WO2009013335A1 (pt) |
| ZA (1) | ZA201000079B (pt) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1932846B1 (en) * | 2005-08-30 | 2010-10-27 | Sumitomo Chemical Company, Limited | Method for producing sulfonyl chloride compound |
| US20110105457A1 (en) * | 2008-04-18 | 2011-05-05 | Shionogi & Co., Ltd. | Heterocyclic compound having inhibitory activity on pi3k |
| WO2012013713A2 (en) * | 2010-07-28 | 2012-02-02 | Bayer Pharma Aktiengesellschaft | Substituted imidazo[1,2-b]pyridazines |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| EP2726482B1 (en) * | 2011-07-01 | 2016-07-20 | Bayer Intellectual Property GmbH | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors |
| WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| PE20181519A1 (es) * | 2011-12-28 | 2018-09-21 | Global Blood Therapeutics Inc | Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido |
| CN107652289B (zh) | 2012-06-13 | 2020-07-21 | 因塞特控股公司 | 作为fgfr抑制剂的取代的三环化合物 |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| SG11201503299YA (en) * | 2012-09-28 | 2015-06-29 | Univ Vanderbilt | Fused heterocyclic compounds as selective bmp inhibitors |
| KR20150072412A (ko) * | 2012-10-05 | 2015-06-29 | 리겔 파마슈티칼스, 인크. | Gdf-8 억제제 |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| AP2015008718A0 (en) | 2013-03-15 | 2015-09-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| BR112015021985B1 (pt) | 2013-03-15 | 2022-12-13 | Global Blood Therapeutics, Inc | Compostos ou sais farmaceuticamente aceitáveis dos mesmos, respectivos usos e composição |
| US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| JP6463327B2 (ja) | 2013-03-15 | 2019-01-30 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンの修飾のための化合物及びその使用 |
| KR102269032B1 (ko) | 2013-04-19 | 2021-06-24 | 인사이트 홀딩스 코포레이션 | Fgfr 저해제로서 이환식 헤테로사이클 |
| RU2550346C2 (ru) * | 2013-09-26 | 2015-05-10 | Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний |
| EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| JP6809681B2 (ja) | 2014-02-07 | 2021-01-06 | グローバル ブラッド セラピューティクス インコーポレイテッド | ２−ヒドロキシ−６−（（２−（１−イソプロピル−１ｈ−ピラゾール−５−イル）ピリジン−３−イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形 |
| WO2015157093A1 (en) * | 2014-04-08 | 2015-10-15 | Rigel Pharmaceuticals, Inc. | 2,3-disubstituted pyridine compounds as tgf-beta inhibitors and methods of use |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| PE20171514A1 (es) | 2015-02-20 | 2017-10-20 | Incyte Corp | Heterociclos biciclicos como inhibidores de fgfr |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
| US11020382B2 (en) | 2015-12-04 | 2021-06-01 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| CN105418615B (zh) * | 2015-12-09 | 2018-02-02 | 北京工业大学 | 苯甲酰胺衍生物及制备和应用 |
| TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| CN106478517A (zh) * | 2016-08-31 | 2017-03-08 | 安徽省鸿鑫生物科技有限公司 | 一种2‑甲基5‑氯哒嗪酮的合成方法 |
| CN106478516A (zh) * | 2016-08-31 | 2017-03-08 | 安徽省鸿鑫生物科技有限公司 | 一种5‑氯哒嗪酮的合成方法 |
| TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN107805252A (zh) * | 2017-10-25 | 2018-03-16 | 上海道亦化工科技有限公司 | 一种基于咪唑并哒嗪的有机电致发光化合物及其用途和有机电致发光器件 |
| CN111433200B (zh) | 2017-12-02 | 2024-03-22 | 加拉帕戈斯股份有限公司 | 用于治疗疾病的化合物及其药物组合物 |
| CN111867581B (zh) | 2018-01-29 | 2023-12-26 | 默克专利股份有限公司 | Gcn2抑制剂及其用途 |
| SG11202006701TA (en) * | 2018-01-29 | 2020-08-28 | Merck Patent Gmbh | Gcn2 inhibitors and uses thereof |
| EP3765460A1 (en) | 2018-03-14 | 2021-01-20 | Vanderbilt University | Inhibition of bmp signaling, compounds, compositions and uses thereof |
| SG11202010636VA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
| BR112020022373A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | sais de um inibidor de fgfr |
| US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
| SG11202106582YA (en) * | 2018-12-20 | 2021-07-29 | Incyte Corp | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 |
| WO2020163689A1 (en) | 2019-02-08 | 2020-08-13 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | 20-hete formation inhibitors |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076602A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN115151539A (zh) | 2019-12-04 | 2022-10-04 | 因赛特公司 | Fgfr抑制剂的衍生物 |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| US20230049619A1 (en) | 2019-12-19 | 2023-02-16 | Universite De Strasbourg | Sigma-1 receptor ligands and uses thereof |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| PE20230491A1 (es) * | 2020-06-12 | 2023-03-23 | Incyte Corp | Compuestos de imidazopiridazina con actividad como inhibidores de alk2 |
| ES2984546T3 (es) | 2020-07-15 | 2024-10-29 | Chiesi Farm Spa | Derivados de amino pirido-oxazina como inhibidores de ALK5 |
| KR20230051500A (ko) | 2020-07-15 | 2023-04-18 | 키에시 파르마슈티시 엣스. 피. 에이. | Alk5 억제제로서 피리다진일 아미노 유도체 |
| US20240116947A1 (en) | 2020-07-15 | 2024-04-11 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine derivatives as alk5 inhibitors |
| WO2022136221A1 (en) | 2020-12-23 | 2022-06-30 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine derivatives as alk5 inhibitors |
| US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
| AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202328102A (zh) | 2021-09-21 | 2023-07-16 | 義大利商吉斯藥品公司 | 作為ａｌｋ５抑制劑之嗒𠯤基胺基衍生物 |
| EP4514802A1 (en) | 2022-04-27 | 2025-03-05 | Chiesi Farmaceutici S.p.A. | Imidazole derivatives as alk5 inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT880523E (pt) | 1996-02-07 | 2007-01-31 | Neurocrine Biosciences Inc | Pirazolopirimidinas com antagonistas dos receptores de crf |
| KR20010087738A (ko) * | 1998-10-21 | 2001-09-21 | 다케다 야쿠힌 고교 가부시키가이샤 | 축합 피리다진 유도체, 이의 제조 방법 및 용도 |
| GB0103926D0 (en) * | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| KR20050115252A (ko) | 2003-02-28 | 2005-12-07 | 데이진 화-마 가부시키가이샤 | 피라졸로[1,5-ａ]피리미딘 유도체 |
| JP4758909B2 (ja) * | 2003-12-31 | 2011-08-31 | シェーリング−プラウ・リミテッド | イミダゾ［１，２−ｂ］ピリダジン誘導体を使用することによる動物における寄生生物の制御 |
| CN101098870B (zh) * | 2004-11-08 | 2010-11-03 | 万有制药株式会社 | 新型稠环咪唑衍生物 |
| JP4971300B2 (ja) | 2005-03-21 | 2012-07-11 | イーライ リリー アンド カンパニー | イミダゾピリダジン化合物 |
| US7557103B2 (en) | 2005-04-05 | 2009-07-07 | Eli Lilly And Company | Imidazopyridazine compounds |
| US7750000B2 (en) | 2005-09-02 | 2010-07-06 | Bayer Schering Pharma Ag | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US20100035918A1 (en) | 2007-01-30 | 2010-02-11 | Biogen Idec Ma Inc | Imidazolone Compounds and Methods of Making and Using the Same |
-
2008
- 2008-07-24 JP JP2010517403A patent/JP5090528B2/ja not_active Expired - Fee Related
- 2008-07-24 US US12/670,188 patent/US8143253B2/en not_active Expired - Fee Related
- 2008-07-24 EP EP08775322A patent/EP2183027B1/en active Active
- 2008-07-24 AT AT08775322T patent/ATE522249T1/de not_active IP Right Cessation
- 2008-07-24 KR KR1020107001656A patent/KR101150581B1/ko not_active Expired - Fee Related
- 2008-07-24 ES ES08775322T patent/ES2375425T3/es active Active
- 2008-07-24 CA CA2694261A patent/CA2694261A1/en not_active Abandoned
- 2008-07-24 WO PCT/EP2008/059705 patent/WO2009013335A1/en not_active Ceased
- 2008-07-24 CN CN200880100481.6A patent/CN101765442B/zh not_active Expired - Fee Related
- 2008-07-24 EA EA201000123A patent/EA201000123A1/ru unknown
- 2008-07-24 AU AU2008280135A patent/AU2008280135B2/en not_active Ceased
- 2008-07-24 BR BRPI0813625-4A2A patent/BRPI0813625A2/pt not_active IP Right Cessation
- 2008-07-24 PE PE2008001257A patent/PE20090506A1/es not_active Application Discontinuation
- 2008-07-25 CL CL2008002184A patent/CL2008002184A1/es unknown
- 2008-07-25 TW TW097128501A patent/TW200911814A/zh unknown
-
2010
- 2010-01-05 ZA ZA201000079A patent/ZA201000079B/xx unknown
- 2010-01-08 CR CR11207A patent/CR11207A/es not_active Application Discontinuation
- 2010-01-22 MA MA32544A patent/MA31571B1/fr unknown
- 2010-01-22 TN TNP2010000040A patent/TN2010000040A1/fr unknown
- 2010-01-25 CO CO10007036A patent/CO6290714A2/es not_active Application Discontinuation
- 2010-01-25 EC EC2010009898A patent/ECSP109898A/es unknown
- 2010-01-26 SV SV2010003463A patent/SV2010003463A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US8143253B2 (en) | 2012-03-27 |
| TW200911814A (en) | 2009-03-16 |
| EP2183027B1 (en) | 2011-08-31 |
| CR11207A (es) | 2010-02-12 |
| ES2375425T3 (es) | 2012-02-29 |
| CO6290714A2 (es) | 2011-06-20 |
| EP2183027A1 (en) | 2010-05-12 |
| CL2008002184A1 (es) | 2009-05-08 |
| ATE522249T1 (de) | 2011-09-15 |
| US20100204235A1 (en) | 2010-08-12 |
| ZA201000079B (en) | 2010-09-29 |
| JP5090528B2 (ja) | 2012-12-05 |
| KR20100034028A (ko) | 2010-03-31 |
| TN2010000040A1 (en) | 2011-09-26 |
| WO2009013335A1 (en) | 2009-01-29 |
| ECSP109898A (es) | 2010-02-26 |
| MA31571B1 (fr) | 2010-08-02 |
| JP2010534633A (ja) | 2010-11-11 |
| AU2008280135B2 (en) | 2012-02-23 |
| PE20090506A1 (es) | 2009-05-28 |
| SV2010003463A (es) | 2010-04-13 |
| KR101150581B1 (ko) | 2012-06-11 |
| CA2694261A1 (en) | 2009-01-29 |
| CN101765442A (zh) | 2010-06-30 |
| CN101765442B (zh) | 2014-09-17 |
| EA201000123A1 (ru) | 2010-08-30 |
| AU2008280135A1 (en) | 2009-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0813625A2 (pt) | Imidazo-[1,2b]-piridozinas 2,3,7-substituídos para tratamento de doenças mediadas por alzk4 ou alk5 | |
| TN2010000167A1 (en) | Organic compounds | |
| TN2010000305A1 (en) | Pyrrolopyrimidines and pyrrolopyridines | |
| JOP20190151B1 (ar) | مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان | |
| PH12018500958A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| PH12016502168A1 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| PH12018500532A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
| BR112013033182A2 (pt) | compostos imidazopiridinil-aminopiridina substituída | |
| EA201001687A1 (ru) | Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 ) | |
| GB0305152D0 (en) | Organic compounds | |
| PT1951730E (pt) | Derivados de pirimidina ligados a heteroalquilo | |
| MY150059A (en) | Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors | |
| EP4480543A3 (en) | Chiral diaryl macrocycle and use thereof in the treatment of cancer | |
| TW200714604A (en) | Substituted heterocycles and the uses thereof | |
| PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| PH12016502394A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| WO2007068473A3 (en) | Organic compounds | |
| WO2012078674A8 (en) | Substituted indole/indazole-pyrimidinyl compounds | |
| UA100390C2 (en) | Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |